OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial



    BOTHELL, WA, and VANCOUVER, May 30 /CNW/ - OncoGenex Pharmaceuticals,
Inc. (NASDAQ:   OGXI) today announced preliminary results of a Phase 1 trial
presented during an oral presentation at the American Society of Clinical
Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed
that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427
demonstrated declines in circulating tumor cells at all doses evaluated as
well as evidence of reduction in tumor markers. Reductions in circulating
tumor cells and tumor markers both suggest single-agent activity warranting
further clinical investigation.
    The Phase 1 trial has evaluated 41 patients with a variety of cancers to
date; enrollment is ongoing. The first phase of the study evaluated increasing
doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was
not identified up to and including the 1000-mg dose of OGX-427 monotherapy.
Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in
combination with docetaxel was evaluated, to be followed by a 1000-mg dose of
OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within
the first 9 days and then continued weekly, with three weeks defined as a
treatment cycle, until disease progression or toxicity. In those groups
receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was
administered on Day 1 of every 3-week cycle starting after completion of the
OGX-427 loading doses.

    Safety Results

    Patients enrolled had a diagnosis of breast, ovarian, prostate or
non-small cell lung cancer and most had failed multiple prior chemotherapy
treatments. A median of 2 cycles (range of 1-8 cycles) was administered with
the following safety results for OGX-427 as monotherapy:

    
    -   Criteria for a maximum tolerated dose were not met at the highest
        dose evaluated as monotherapy (1000 mg).

    -   No evidence of altered cardiac activity was observed.

    -   Majority of adverse events were mild and mainly occurred during the
        loading doses. Adverse events consisted of chills, itching and
        fatigue in over a third of patients.

    -   There was a trend for increasing incidence of some mild adverse
        events with escalating OGX-427 doses. For example, 33% of patients at
        the 200-mg dose compared to 67% of patients at the 1000-mg dose had
        mild adverse events during the loading doses.

    -   The half-life of OGX-427 in the blood remained constant, although
        there appeared to be an increase in maximum blood levels and a
        corresponding decease in blood clearance of OGX-427 as doses were
        escalated.
    

    The combination of 800 mg OGX-427 with docetaxel was also well tolerated
and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

    Circulating Tumor Cell and Tumor Marker Results

    Circulating tumor cells (CTCs), an emerging metric to assess treatment
effect, was evaluated at baseline before treatment and during treatment. Both
total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in
both total and Hsp27-positive CTCs were observed in over half of the patients
in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or
less cells occurred in 27% of patients who had greater than 5 CTCs at
baseline.
    Reduction in tumor markers defined as declines of PSA levels in prostate
cancer or CA-125 levels in ovarian cancer were also observed. A reduction in
PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a
reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian
cancer.
    "CTCs are emerging as an exciting surrogate of anti-cancer activity. The
frequent decreases in total and Hsp-27 positive CTC counts, coupled with
decreases in serum PSA and CA-125 levels in patients with prostate and ovarian
cancer, markers that strongly suggest single agent anti-cancer activity for
OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical
oncologist at Juravinski Cancer Centre, Hamilton, Ontario.
    "We are very satisfied with the safety profile of OGX-427 to date in this
trial and the early, strong indicators of anti-tumor and biological activity,"
said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

    About OGX-427

    OGX-427 is designed to reduce production of Hsp27, a protein that is
over-produced in response to many cancer treatments including hormone ablation
therapy, chemotherapy and radiation therapy. Hsp27 production has been shown
to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427
is being evaluated in a Phase 1 clinical trial for the treatment of solid
tumors including prostate, non-small cell lung, breast, ovarian, and bladder
cancers. Like OGX-011, this product candidate has potential as a treatment in
a broad number of cancers.

    About OncoGenex

    OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address unmet needs in the treatment
of cancer. OncoGenex has a deep oncology pipeline, with each product candidate
having a distinct mechanism of action and representing a unique opportunity
for cancer drug development. OGX-011, the lead candidate currently completing
five Phase 2 clinical studies in prostate, lung and breast cancers, is
designed to inhibit the production of a specific protein associated with
treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has
completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently
in pre-clinical development.
    OGX-011, OGX-427 and OGX-225 utilize second-generation antisense
technology, licensed from Isis Pharmaceuticals (NASDAQ:   ISIS), to effectively
target and inhibit production of specific proteins in tumor cells. OncoGenex
and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225
and with respect to OGX-011, in its initial development. In 2008, OncoGenex
and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights
to OGX-011 and sole responsibility for development and related costs and
partnering decisions, subject to financial obligations to Isis. OncoGenex is
also solely responsible for development and related costs and partnering
decisions regarding OGX-427 and OGX-225. Key intellectual property related to
OGX-011, OGX-427 and OGX-225 were discovered by the University of British
Columbia and the Vancouver Prostate Centre, and were exclusively licensed to
OncoGenex.
    More information about OncoGenex is available at www.oncogenex.com.

    This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995, including statements concerning the potential survival benefit of
OGX-011, anticipated clinical development activities, timing of these
activities, the ability of future trials to demonstrate clinical benefit and
the potential for regulatory approvals. All statements other than statements
of historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current expectations
and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those
described in the forward-looking statements.
    The potential risks and uncertainties associated with forward-looking
statements include, among others, the possibility that any benefit in patient
survival will not be maintained or will become less substantial as patient
survival follow up continues, risks that clinical trials will not be
successful or confirm earlier clinical trial results, including the risk that
the survival benefit will not be confirmed by a Phase 3 clinical trial, risks
associated with obtaining funding from third parties or completing a financing
necessary to support the costs and expenses of a Phase 3 clinical trial, the
timing and costs of clinical trials and regulatory approvals will be different
than management currently anticipates, risks relating to the development,
safety and efficacy of therapeutic drugs and potential applications for these
products and the risk factors set forth in the Company's filings with the
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K for fiscal year 2008. The Company undertakes no obligation to update
the forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof.





For further information:

For further information: OncoGenex Contact: Scott Cormack, President &
CEO, (604) 736-3678, scormack@oncogenex.com; Media and Investor Contact: Jason
Spark, Porter Novelli Life Sciences, (619) 849-6005,
jspark@pnlifesciences.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890